Evidence‐based therapies that have proven beneficial in other causes of heart failure, including angiotensin‐converting enzyme (ACE) inhibitors, angiotensin receptor blockers (ARBs), angiotensin receptor neprilysin inhibitors (ARNIs), and beta blockers are generally poorly tolerated in patients with advanced cardiac amyloidosis owing to fixed stroke volume and impaired hemodynamic compensatory mechanisms and worsens hypotension and discontinuation may improve outcomes [15, 19, 20, 21]. Here, ACE is linked to heart failure.